Clinical characterization of Kidney Injury Molecule-1 (KIM-1) as a Biomarker in Renal Cell Carcinoma

项目摘要 虽然转移性肾细胞癌患者有许多治疗选择，但它仍然是一种致命的疾病， 相当高的死亡率。如果及早发现肾癌，可以更有效地治疗它。 做手术。到目前为止，还没有RCC的生物标志物。此外，一种特异而灵敏的循环生物标志物 不仅有助于更早地发现这种癌症，而且还可以帮助诊断和监测疾病。 这项建议旨在测试循环肾脏损伤分子-1/T细胞免疫球蛋白粘蛋白的效用 DOMAIN-1(KIM-1/TIM-1)作为一种血液检测，可用于跟踪肾小肿块患者和 安全地避免或推迟手术的目标。我们还将测量肾癌切除患者的KIM1。 确定最有可能从辅助治疗中受益的高危患者群体的目标是 肾切除术用于局部疾病。这项提议还将测试Kim-1作为一种血液测试，这可能会有所帮助 跟踪转移性疾病的治疗反应。为了准备提交，我们的团队花了很多时间 花相当多的时间和精力寻找现成的患者样本来回答我们的问题。在……里面 这项提案我们已经做好了准备，并准备好了解决所有这些问题的样本。我们希望在 未来，前瞻性试验将在这些环境中测试KIM-1，但此时，在这些环境中进行严格的测试 回溯性队列将为这些未来的研究提供基础。

Project Summary While there are many treatment options for patients with metastatic RCC, it is still a deadly disease with considerable mortality. RCC can be much more effectively treated if it is detected early when it is amenable to surgery. To date there is no biomarker for RCC. Additionally, A specific and sensitive circulating biomarker could not only help detect this cancer earlier but could also aid in the diagnosis and monitoring of disease. This proposal seeks to test the utility of circulating kidney injury molecule-1/ T cell immunoglobulin mucin domain-1 (KIM-1/ TIM-1) as a blood test that can be used to follow patients with small renal masses and with the goal of safely avoiding or delaying surgery. We will also measure KIM1 in patients with resected RCC with the goal of identifying a high-risk patient population most likely to benefit from adjuvant therapy after nephrectomy for localized disease. This proposal will also test KIM-1 as a blood test that can help follow response to therapy for metastatic disease. To prepare for submission our team has spent considerable time and effort in identifying readily available patient samples to answer our questions. In this proposal we are poised and have samples available to address all of these questions. We hope that in the future, prospective trials will test KIM-1 in these settings but at this time, rigorous testing in these retrospective cohorts will provide the groundwork for these future studies.